Condition: Prostate Cancer · Sponsor: Weill Medical College of Cornell University
This is a phase I dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA small molecule. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates (radiation linked to antibodies/molecules that recognize prostate cancer cells). This phase of the study (phase I) will determine the highest dose of the study intervention that can be safely given.
This description comes directly from the study's public registry record.
GUONC Research Team · 212-746-1480 · guonc@med.cornell.edu
Always discuss trial participation with your own doctor first.
| Brooklyn Methodist Hospital - New York Presbyterian | Brooklyn, New York, United States | Recruiting |
| Weill Cornell Medicine New York Presbyterian | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04886986